Abstract 1561P
Background
Recently, we reported safety and efficacy of T-mab plus N-mab with S-1/Capecitabine plus oxaliplatin (UMIN000034222). The aim of this study was to explore a candidate biomarker for this new combination therapy.
Methods
Patients were treated with S-1 80 mg/m2/day or Capecitabine 2000 mg/m2/day on days 1-14 with oxaliplatin 130 mg/m2, N-mab 360mg, and T-mab 8mg/kg for initial treatment, and subsequently with 6 mg/kg on day 1, repeated every 3 weeks. Pre-treatment primary tumor samples were collected for whole exome sequencing (WES).
Results
42 patients enrolled in this clinical trial, and WES was performed on 23 patients. In the copy number analysis, ERBB2 amp. was observed most frequently in 15 patients (65%). Subsequently, GATA6, MYC and CCNE1 amp. were observed in 8 (35%), 6 (26%), and 5 (22%) patients, respectively. In the mutation analysis, TP53 was observed most frequently in 20 patients (87%). Subsequently, mutations in APC, ERBB3, and PIK3CA were observed in 6 (26%), 3 (13%), and 3 (13%) patients, respectively. Among them, APC mut., MYC, and GATA6 amp. were associated with worse survival. Patients with APC mut. showed significantly shorter PFS (median 5.6 vs 20.8 months, HR 3.47, 95%CI 1.16-10.44, p = 0.018), but not for OS (median 21.0 vs 26.5 months, HR 1.19, 95%CI 0.31-4.60, p = 0.806). Patients with MYC amp. showed significantly shorter PFS (median 4.2 vs 18.0 months, HR 3.48, 95%CI 1.09-11.12, p = 0.024) and OS (median 13.9 months vs not reached, HR 3.97, 95%CI 0.95-16.54, p = 0.042), respectively. Patients with GATA6 amp. showed significantly shorter PFS (median 5.8 vs 32.0 months, HR 3.53, 95%CI 1.25-9.99, p = 0.011) and OS (median 13.9 months vs not reached, HR 3.74, 95%CI 1.04-13.40, p = 0.030). As for objective response rates (ORRs), patients with APC mut. and MYC amp. showed lower response rates (50% vs 82% for APC mut., 67% vs 77% for MYC amp.), whereas comparable ORR was shown for GATA6 amp. (75% vs 73 %).
Conclusions
APC mut., MYC, and GATA6 amp. may have negative clinical impacts on the effects of the new combination therapy including T-mab and N-mab.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ono Pharmaceutical Co., Ltd.
Disclosure
K. Chin: Financial Interests, Personal, Speaker’s Bureau: Taiho Pharma, Ono Pharmaceutical Co.Ltd., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Merck & Co., Inc. K. Minashi: Financial Interests, Institutional, Research Grant: Amgen, Taiho, Daiichi Sankyo Co., Ltd, Astellas Pharmaceutical Co., Ltd,. H. Hara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, MSD, Ono, Bayer, Chugai, Lilly, Merck Biopharma, Taiho, Takeda, Yakult, Bristol Myers Squibb; Financial Interests, Institutional, Coordinating PI: Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Janssen, Merck Biopharma, MSD, Ono, Taiho, ALX oncology. K. Kato: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Bristol Myers Squibb, Merck and Co; Financial Interests, Personal, Advisory Board: Ono Pharmaceutical, Bristol Myers Squibb, Merck and Co, Bayer, AstraZeneca, BeiGene, Taiho, Merck Biophrma, Amgen, Novartis, Daiichi Sankyo; Financial Interests, Institutional, Coordinating PI: Ono Pharmaceuticals, Merck & Co; Financial Interests, Institutional, Local PI: Bayer, AstraZeneca, BeiGene, Chugai, Taiho, Oncolys Biopharma, Janssen Pharmaceutical. N. Boku: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Eli Lilly, Ono Pharmaceutical, Taiho, Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Takeda Pharmaceutical, Ono Pharmaceutical. K. Yamaguchi: Financial Interests, Personal, Invited Speaker: Taiho; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Bristol Myers Squibb, Ono, Eli Lilly Japan; Financial Interests, Institutional, Funding: Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21